Aduro Biotech, Inc. (Nasdaq:ADRO) today highlighted two posters
presented at the Second CRI-CIMT-EATI-AACR International Cancer
Immunotherapy Conference (CRI-AACR) in New York. The preclinical
data demonstrate positive changes in the tumor microenvironment and
induction of a tumor-specific immune response by Aduro’s LADD
(listeria-based immunotherapy construct) and STING (Stimulator of
Interferon Genes) Pathway Activator immunotherapy platform
technologies. Importantly, adding a PD-1 blockade to either
immunotherapy regimen significantly bolstered antitumor efficacy.
“These preclinical data demonstrate the underlying mechanisms by
which our LADD and STING immunotherapy platforms activate the
immune system and induce robust innate immunity, facilitating a
change in the tumor microenvironment which results in effective
destruction of cancer cells in several preclinical models,” said
Thomas Dubensky, Jr., Ph.D., chief scientific officer of Aduro.
“Importantly, the combination data are even more impressive,
showing increased efficacy when our LADD and STING platforms are
combined with an anti-PD1 checkpoint inhibitor to combat the
tumor’s ability to hide from the immune system. These data
support our strategy to combine our immunotherapy regimens with
checkpoint inhibitors for greater anti-tumor activity, looking
toward the ultimate goal of better, more effective patient
care.”
The following posters were presented at the meeting:
Poster A013: Favorable changes in the tumor
microenvironment following intravenous dosing with live attenuated
Listeria monocytogenes-based immunotherapy.In a poster
session on Sunday, September 25, 2016, Meredith Leong, Ph.D., a
scientist at Aduro, presented data from multiple preclinical
studies using Aduro’s LADD immunotherapy platform. The data
demonstrated that a combination of LADD with an anti-PD1 checkpoint
inhibitor results in improved anti-tumor efficacy in multiple tumor
models. In addition, analyses of biopsies from patients given
CRS-207, a LADD immunotherapy, showed enhancement of infiltrating
CD8+ T cells, mature dendritic cells, macrophages and natural
killer cells, all specialized immune system cells involved in
eradicating tumor cells. Consistent with this clinical data, the
preclinical findings showed that LADD induced a potent favorable
change in the tumor microenvironment including increased CD8+ T
cells, infiltration of neutrophils, and a reduction of regulatory T
cells, creating an environment for the tumor susceptible to
anti-cancer treatments.
Poster B020: STING activation in the tumor
microenvironment using a synthetic human STING-activating cyclic
dinucleotide induces potent anti-tumor immunityIn a poster
session on Monday, September 26, 2016, Sarah McWhirter, Ph.D., a
scientist at Aduro, presented preclinical data on ADU-S100, a STING
Pathway Activator. The data demonstrate that ADU-S100 stimulates
the production of interferon-beta by all human STING alleles.
Importantly, the results showed that injecting ADU-S100 directly
into the tumor microenvironment induced T cells with tumor-specific
antigenic repertoire leading to durable anti-tumor immunity. In
addition, the combination of STING activation in the tumor
microenvironment and PD-1 blockade enhances antitumor efficacy.
There is an ongoing Phase 1 first-in-human clinical study to
evaluate the safety, tolerability and possible anti-tumor activity
of ADU-S100 in patients with cutaneously-accessible advanced
metastatic solid tumors or lymphomas.
About the Tumor Microenvironment The tumor
microenvironment is the cellular environment in which the tumor
exists, and, along with cancerous cells, includes support cells,
immune cells, surrounding blood vessels, and the extracellular
matrix. The tumor cells and the surrounding microenvironment are
closely related and interact constantly. Tumors influence the
microenvironment by releasing signals that promote tumor growth,
immune tolerance and immune suppression. When tumors initially
form, the body’s immune system recruits and activates a host of
immune cells to fight the invading tumor. However, in cases where
cancer develops, tumors are eventually able to evade the immune
system by changing their microenvironment to inhibit the ability of
the immune system to recognize and destroy the tumor thus allowing
for tumor outgrowth and formation of metastasis.
About LADD and
CRS-207 LADD is Aduro's proprietary platform of live,
attenuated double-deleted Listeria monocytogenes strains that have
been engineered to generate a potent innate immune response and to
express tumor-associated antigens to induce tumor-specific T
cell-mediated immunity.
CRS-207 is one of a family of product candidates based on
Aduro's LADD immunotherapy platform that has been
engineered to express the tumor-associated antigen mesothelin,
which is over-expressed in many cancers including mesothelioma and
pancreatic, non-small cell lung, ovarian, endometrial and gastric
cancers.
About STING Pathway Activator Platform The
Aduro-proprietary STING Pathway Activator product candidates,
including ADU-S100 (MIW815), are synthetic small molecule immune
modulators that are designed to target and activate human STING.
STING is generally expressed at high levels in immune cells,
including dendritic cells. Once activated, the STING receptor
initiates a profound innate immune response through multiple
pathways, inducing the expression of a broad profile of cytokines,
including interferons and chemokines. This subsequently leads to
the development of a systemic tumor antigen-specific T cell
adaptive immune response.
About Aduro Aduro Biotech, Inc. is an
immunotherapy company focused on the discovery, development and
commercialization of therapies that transform the treatment of
challenging diseases. Aduro's technology platforms, which are
designed to harness the body's natural immune system, are being
investigated in cancer indications and have the potential to expand
into autoimmune and infectious diseases. Aduro's LADD technology
platform is based on proprietary attenuated strains of Listeria
that have been engineered to express tumor-associated antigens to
induce specific and targeted immune responses. This platform is
being developed as a treatment for multiple indications, including
pancreatic, ovarian, lung and prostate cancers, mesothelioma and
glioblastoma. Aduro's STING Pathway Activator platform is designed
to activate the intracellular STING receptor, resulting in a potent
tumor-specific immune response. ADU-S100 is the first STING Pathway
Activator compound to enter the clinic and is currently being
evaluated in a Phase 1 study in patients with cutaneously
accessible metastatic solid tumors or lymphomas. Aduro’s B-select
monoclonal antibody platform includes a number of immune modulating
assets in research and preclinical development. Aduro is
collaborating with leading global pharmaceutical companies to
expand its products and technology platforms. For more information,
please visit www.aduro.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding our intentions or current expectations
concerning, among other things, the potential for our technology
platforms, plans, and the potential for eventual regulatory
approval of our product candidates. In some cases, you can identify
these statements by forward-looking words such as “may,” “will,”
“continue,” “anticipate,” “intend,” “could,” “project,” “expect” or
the negative or plural of these words or similar expressions.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results and events to differ materially from those anticipated,
including, but not limited to, our history of net operating losses
and uncertainty regarding our ability to achieve profitability, our
ability to develop and commercialize our product candidates, our
ability to use and expand our technology platforms to build a
pipeline of product candidates, our ability to obtain and maintain
regulatory approval of our product candidates, our inability to
operate in a competitive industry and compete successfully against
competitors that have greater resources than we do, our reliance on
third parties, and our ability to obtain and adequately protect
intellectual property rights for our product candidates. We
discuss many of these risks in greater detail under the heading
“Risk Factors” contained in our quarterly report on Form 10-Q for
the quarter ended June 30, 2016, which is on file with
the Securities and Exchange Commission. Any forward-looking
statements that we make in this press release speak only as of the
date of this press release. We assume no obligation to update our
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Contact:
Sylvia Wheeler
SVP, Corporate Affairs
510 809 9264
Media Contact:
Angela Bitting
925 202 6211
press@aduro.com
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Sep 2023 to Sep 2024